Company continuing to advance DNase-based oncology program towards clinical proof-of-concept studies in multiple indications
Xenetic Biosciences Extends Research Agreement With University of Virginia For Advancement Of DNase-Based Oncology Platform
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.